-
12-lead ECG obtained from a 50-year old African American man with hypertension and chest pain.
-
FDA warnings for existing drugs dominate pharmaceutical news this month.
-
Serum analysis of 45 subjects for antibodies and humoral immunity over a median of 15 years showed antiviral responses ranging from 11-19 years for tetanus-diphtheria, 50 years for varicella-zoster, and up to 200 years for measles and mumps.
-
The FDA has approved a non-halogenated nasal steroid for use in pediatric patients aged 6 to 12 years and adults. Ciclesonide is a prodrug that was previously approved for adults and adolescents but was not marketed. It's to be marketed by Nycomed US Inc. as Omnaris.
-
The perception of health care risks motivates behaviors in healthcare workers as well as patients.
-
Lipid abnormalities can be problematic in HIV-positive patients receiving highly active antiretroviral therapy (HAART) due to the risk of premature coronary artery disease developing in susceptible patients.
-
Increasingly, hospitals are being required to make public their surveillance data on hospital-related infections as quality indicators.
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
-
-
Patients with epilepsy are unaware of most of their seizures. Video-EEG is the most reliable method to accurately determine seizure frequency.
